Table of contents


Please note that this product was withdrawn from the Community register of designated orphan medicinal products in April 2013 on request of the sponsor.

On 6 March 2002, orphan designation (EU/3/02/086) was granted by the European Commission to Axcan Pharma International BV, the Netherlands, for porfimer sodium (for use with photodynamic therapy) for the treatment of high-grade dysplasia in Barrett's oesophagus.

Porfimer sodium (for use with photodynamic therapy) was authorised in the EU as PhotoBarr on 25 March 2004.

The sponsorship was transferred to Pinnacle Biologics B.V., the Netherlands, in August 2011.

The marketing authorisation was withdrawn on 20 April 2012.

Key facts

Active substance
Porfimer sodium (for use with photodynamic therapy)
Medicine name
Disease / condition
Treatment of high-grade dysplasia in Barrett's oesophagus
Date of first decision
EU designation number

Sponsor's contact details

Pinnacle Biologics B.V.
p/a Trust Company Amsterdam B.V.
Crystal Tower 21st Floor
Orlyplein 10
1043 DP Amsterdam
The Netherlands
Tel. +31 20 386 86 22
Fax +31 20 203 11 96
Contact us

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating